Tergene Biotech is one of the innovative biotechnology companies engaged in the development of vaccines and bio-therapeutics. Tergene has developed platform technologies for novel vaccine candidates. The company has also supported many other biotech companies and research institutions by supplying them with CRM197 carrier protein, mainly used in conjugate vaccines and cancer research.

In the year 2015, Tergene entered into a joint venture with Aurobindo Pharma Limited, a 2 billion dollar Indian Pharma giant. Tergene is now a subsidiary of Aurobindo Pharma.

Dr. M. Kuppusamy, Founder & Managing Director 

A scientist turned entrepreneur with an experience of over 4 decades in the field of vaccines and biopharmaceuticals. He received his basic training in vaccine manufacturing from the renowned Pasteur Institute of India. He had the opportunity to serve the Indian Council for Medical Research from 1986 to 1992. During his term in ICMR, he invented a unique thrombolytic enzyme called “Thrombinase” which was granted a product patent in the USA.

Mr. K. Sathyan, Co-founder & Whole-time Director 

A tech-entrepreneur and professional. He promoted Samies Technologies Pvt Ltd, a software company dealing with e-commerce & software solutions. At Samies, he had been the man behind establishing a large client base in the USA which has helped the company’s business to grow vertically. In the field of biotech, prior to promoting Tergene, he was involved in setting up a biotech plant for the production of Typhoid and Hib vaccines.